España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
BriaCell Therapeutics
BCTX
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.760000
-0.16
-17.49%
At Close: -
$0.760000
0
0.00%
Pre-Market: 7:04 AM EDT
15 minutes delayed
Get Report
Comment
BriaCell Therapeutics (BCTX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for BriaCell Therapeutics (NASDAQ:BCTX) Stock
BriaCell Therapeutics Stock (NASDAQ: BCTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, July 18, 2024
BriaCell Reports Extended Progression-Free Su...
Benzinga Newsdesk
Tuesday, June 04, 2024
HC Wainwright & Co. Reiterates Buy on BriaCel...
Benzinga Newsdesk
Monday, June 03, 2024
BriaCell Presents Clinical Efficacy Data Of R...
Benzinga Newsdesk
Thursday, May 30, 2024
BriaCell Starts Patient Enrollment In First-i...
Benzinga Newsdesk
Tuesday, May 28, 2024
BriaCell Therapeutics Announces Clinical Supp...
Benzinga Newsdesk
Friday, May 24, 2024
BriaCell Doubles Progression-Free-Survival An...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on BriaCel...
Benzinga Newsdesk
Wednesday, May 15, 2024
BriaCell Therapeutics shares are trading lowe...
Benzinga Newsdesk
BriaCell Therapeutics Announces Pricing Of $5...
Benzinga Newsdesk
Wednesday, April 10, 2024
BriaCell 2024 AACR Preclinical Poster Confirm...
Benzinga Newsdesk
Tuesday, April 09, 2024
BriaCell Highlights Data For Antibody-Drug Co...
Benzinga Newsdesk
Thursday, March 07, 2024
BriaCell Receives And Executes Letter Of Inte...
Benzinga Newsdesk
Wednesday, March 06, 2024
BriaCell To Present Clinical Data In Central ...
Benzinga Newsdesk
Tuesday, February 27, 2024
BriaCell Provides Update On Alleged Illegal T...
Benzinga Newsdesk
Wednesday, February 07, 2024
BriaCell Reports Prelim Disease Control Rate ...
Benzinga Newsdesk
Monday, January 22, 2024
Briacell Therapeutics Filed For Mixed Shelf Offering Of Up To $200M
Charles Gross
Thursday, January 04, 2024
BriaCell Images Confirm Robust Anti-Tumor Act...
Benzinga Newsdesk
Thursday, December 28, 2023
HC Wainwright & Co. Reiterates Buy on BriaCel...
Benzinga Newsdesk
BriaCell Reports 71% Central Nervous System R...
Benzinga Newsdesk
Wednesday, December 20, 2023
BriaCell Therapeutics' Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated Patients
Vandana Singh
BriaCell Therapeutics Reports Preliminary Sur...
Benzinga Newsdesk
Wednesday, December 06, 2023
BriaCell Highlights Outstanding Topline Survi...
Benzinga Newsdesk
BriaCell 2023 SABCS Posters Confirm Activatio...
Benzinga Newsdesk
Friday, November 03, 2023
BriaCell Reports Unprecedented Anti-Tumor Act...
Benzinga Newsdesk
Wednesday, October 25, 2023
BriaCell Forms Medical Advisory Board Of Dist...
Benzinga Newsdesk
Wednesday, October 11, 2023
BriaCell To Host Virtual Key Opinion Leader E...
Benzinga Newsdesk
Wednesday, October 04, 2023
BriaCell Partners With New York Cancer & Bloo...
Bill Haddad
Tuesday, October 03, 2023
HC Wainwright & Co. Maintains Buy on BriaCell...
Benzinga Newsdesk
BriaCell Therapeutics Initiates Phase 3 Study...
Benzinga Newsdesk
Friday, September 08, 2023
BriaCell Reports Benchmark-Beating Patient Su...
Benzinga Newsdesk
Thursday, August 31, 2023
BriaCell Accepts Letter Of Intent From Weill ...
Benzinga Newsdesk
Friday, August 25, 2023
BriaCell Receives Court Approval For the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) To Existing Shareholders; August 31, 2023 Is The Expected Effective Date For The Distribution Contemplated By The Arrangement
Happy Mohamed
Wednesday, August 16, 2023
Briacell Awarded National Cancer Institute Gr...
Benzinga Newsdesk
Wednesday, June 28, 2023
HC Wainwright & Co. Reiterates Buy on BriaCel...
Benzinga Newsdesk
Tuesday, June 27, 2023
BriaCell Therapeutics Has Received Approval F...
Benzinga Newsdesk
Thursday, May 25, 2023
BriaCell Enters Definitive Arrangement Agreement For The Spin Out Of BriaPro Therapeutics Corp.; 1 BriaCell Common Share And 1 Spinco Share For Each BriaCell Common Share That Was Issuable Upon Exercise Of The BriaCell Warrant
Happy Mohamed
Monday, May 15, 2023
BriaCell Announces $4M Strategic Investment And Clinical Alliance With Prevail Partners, LLC And Prevail InfoWorks, Inc.
Happy Mohamed
Thursday, March 30, 2023
BriaCell Announces Intention To Spin-Out Certain Pre-Clinical Assets Into A Newly Created "SpinCo" Entity Whereby Shareholders To Receive One New Share Of "SpinCo" In Addition To Each Current Share Of BriaCell Already Held
Happy Mohamed
Friday, February 24, 2023
HC Wainwright & Co. Reiterates Buy on BriaCel...
Benzinga Newsdesk
Thursday, February 23, 2023
BriaCell Reports Survival Data In Advanced Metastatic Breast Cancer
Happy Mohamed
Friday, February 10, 2023
Reported Late Thursday Feb 9, BriaCell Therapeutics Corp. Announces Results Of Shareholder Meeting; Approval Of The Company's New Omnibus Equity Incentive Plan
Happy Mohamed
Tuesday, January 24, 2023
BriaCell Therapeutics Granted U.S. Patent# 11559574: Whole-cell Cancer Vaccines And Methods For Selection Thereof
Charles Gross
BriaCell CEO Letter To Shareholders
Benzinga Newsdesk
Monday, January 23, 2023
BriaCell To Investigate Alleged Illegal Tradi...
Benzinga Newsdesk
Wednesday, January 18, 2023
BriaCell Announces End Of Phase II Meeting With FDA For Bria-IMT Combination In Advanced Metastatic Breast Cancer; FDA Has Agreed On Primary Endpoint
Bill Haddad
Tuesday, January 10, 2023
BriaCell Announces New Patent Issuance, Bria-...
Benzinga Newsdesk
Tuesday, December 13, 2022
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Ernest Dela Aglanu
-
Sponsored
Thursday, December 01, 2022
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Faith Ashmore
-
Sponsored
Wednesday, November 30, 2022
IPA's Subsidiary BioStrand And BriaCell Announce Artificial Intelligence Collaboration And License Agreement To Discover And Develop Anti-Cancer Antibodies
Bill Haddad
Tuesday, November 15, 2022
Earlier Reported, BriaCell CEO Discusses Clin...
Benzinga Newsdesk
Show More